Latest News for: cll

Edit

U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

PR Newswire 20 Feb 2026
This milestone updates the treatment of CLL in the first-line setting, establishing the VENCLEXTA and acalabrutinib combination as the first and only all-oral, fixed-duration regimen for previously untreated patients.
Edit

BeOne Medicines’ Novel BCL2 Inhibitor, Sonrotoclax, Achieves First-in-World Approval in R/R MCL and R/R CLL/SLL (BeOne Medicines AG)

Public Technologies 06 Jan 2026
In the Phase 2 open-label study of patients with R/R CLL/SLL treated with sonrotoclax (n=100), ORR as assessed by IRC was 77% ... Chronic lymphocytic leukemia (CLL) is a life-threatening cancer of adults.
  • 1

Article Search

tools
×
×
×
×